rose bengal disodium + anti-CTLA-4 therapy

Rose bengal disodium + anti-CTLA-4 therapy is a combination of a small molecule photosensitizer (rose bengal disodium, also known as PV-10) and pharmacological immune checkpoint inhibition (anti-CTLA-4 antibody or nanobody). Rose bengal is used for direct intralesional injection or photodynamic therapy; upon light activation, it generates reactive oxygen species resulting in tumor cell death via apoptosis and necrosis, potentially exposing tumor antigens. This cell death may stimulate tumor-specific immunogenicity, including cytotoxic T-cell responses and bystander effects on distant tumors. Anti-CTLA-4 therapy—through monoclonal antibodies or nanobodies—acts by inhibiting CTLA-4, an immune checkpoint that downregulates immune activation, resulting in enhanced T-cell priming and activation. Combination regimens are under investigation to maximize local and systemic anti-tumor immunity: rose bengal induces tumor cell death and antigen release, while anti-CTLA-4 therapy boosts T-cell responses by blocking inhibitory signals on T cells. Key indications are metastatic melanoma and other solid tumors, especially in settings where immune priming and checkpoint inhibition may synergize.

Brand names

PV-10PV10PV 10

Other names

rose bengal disodiumanti-CTLA-4 antibodyanti-CTLA4 antibodyanti-CTLA 4 antibodyanti-CTLA-4 nanobodyanti-CTLA4 nanobodyanti-CTLA 4 nanobodyanti-CTLA-4 therapyanti-CTLA4 therapyanti-CTLA 4 therapyanti-CTLA-4 monoclonal antibodyanti-CTLA4 monoclonal antibodyanti-CTLA 4 monoclonal antibody